NeoGenomics Inc. (NEO)
NASDAQ: NEOHealth CarePrecision InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NEO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.92B
- Forward P/E
- 47.11
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 7.07 – 20.15
- Day range
- 14.63 – 15.14
- Volume / Avg
- 1.18M / 1.96M
- Beta
- —
- Shares outstanding
- 129.39M
52-week range
NEO stock today
On Nov 20, NEO ended the session at $14.82, shedding $0.27 (1.79%), versus the S&P 500's 3.70% decline. At this level, NEO sits in the middle of its 52-week range of $7.07 to $20.15: 26.5% below the high, set on Oct 6, 2026 and 109.6% above the low. NEO is up 26.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 29.1%.
NeoGenomics has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NeoGenomics
Company profileNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
- Sector
- Health Care
- Industry
- Precision Instruments
- CEO
- Mr. Anthony P. Zook
- Headquarters
- Fort Myers, FL
- Employees
- 2,500
- Website
- neogenomics.com
Financial highlights
Full financialsIn fiscal 2025, NeoGenomics generated $727.3 million in revenue, up 10.1% from fiscal 2024, its 10th consecutive year of revenue growth. NeoGenomics reported a net loss of $108.0 million, compared with a loss of $78.7 million a year earlier. Gross margin was 43.2% (down from 43.9%) and operating margin -15.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $727.33M | $660.57M | $591.64M | $509.73M | $484.33M |
| Growth | +10.11% | +11.65% | +16.07% | +5.24% | +8.97% |
| Net income | $-108.03M | $-78.73M | $-87.97M | $-144.25M | $-8.35M |
| EPS (diluted) | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 |
Analyst forecast
ForecastConsensus (11 analysts)
none
Avg. price target
$23.40+57.89%
- Strong buy 2
- Buy 6
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.05 vs $-0.01
- Surprise
- -400.00%
NEO news
All NEO news- NeoGenomics Touts 29% Sequencing Growth, Plans Sales Push for Cancer TestsNasdaq
- NeoGenomics (NEO) Q3 2026 Earnings Call TranscriptNasdaq
- NeoGenomics raises 2026 guidance to $807M-$809M while planning CEO transition in January 2027Seeking Alpha
- NeoGenomics, Inc. Reports Third Quarter 2026 Total Revenue of $209 millionNasdaqNEO, SUN
- NeoGenomics Reports Third Quarter 2026 ResultsBusiness Wire
- NeoGenomics expands Indica Labs partnership for precision oncologySeeking Alpha
- NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026Business Wire
- Stryker, Neogenomics Announce CEO Transitions; Both Stocks DiveInvestor's Business DailyNEO, SYK
NeoGenomics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AIDX20/20 Biolabs Inc. | 0.1571 | -13.49% | $2.20M | vs NEO |
| ULSUL Solutions Inc. Class A | 72.64 | -2.99% | $14.67B | vs NEO |
Indexes, lists and sector
NeoGenomics stock FAQ
What is NeoGenomics's stock price today?
NEO last traded at $14.82 as of Nov 20, 4:00 PM EST, down 1.79% on the day. Prices are delayed at least 15 minutes.
Who is NeoGenomics's CEO?
Mr. Anthony P. Zook is the chief executive officer of NeoGenomics Inc., which has about 2,500 employees.
What is the NEO 52-week high?
The 52-week high for NEO is $20.15 and the 52-week low is $7.07. The stock is currently 26.5% below its high.